|
AU2015279321A1
|
|
Multispecific antigen binding proteins
|
|
TW201311723A
|
|
Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
|
|
CN106963947A
|
|
NK cells adjustment for the treatment of and the method for treating Hematological Malignancies
|
|
EP2150258A2
|
|
Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
|
|
CN101300272A
|
|
Compositions and methods for treating proliferative disorders
|
|
US2008196112A1
|
|
Transgenic Animals and Methods of Making Recombinant Antibodies
|
|
US2008207568A1
|
|
Class of γδ T cells activators and use thereof
|
|
CN101107269A
|
|
Monoclonal antibodies against NKG2A
|
|
EP1831258A2
|
|
Monoclonal antibodies against nkg2a
|
|
WO2006067635A2
|
|
USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
|
|
CN104645327A
|
|
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
